Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulatory T cells: a potential target in cancer immunotherapy

(2018) Kohei Shitara et al.   Annals of the New York Academy of Sciences

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

(2018) Ranee Mehra et al.   BRITISH JOURNAL OF CANCER

Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma

(2018) Juan Lu et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer

(2018) Takuma Matoba et al.   INTERNATIONAL JOURNAL OF CANCER

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

(2018) Danbee Ha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

(2016) S Bowyer et al.   BRITISH JOURNAL OF CANCER

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori

(2016) Hirotsugu Nagase et al.   INTERNATIONAL JOURNAL OF CANCER

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

(2016) Takuro Saito et al.   NATURE MEDICINE

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

(2016) Baihao Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

(2015) K. Kurose et al.   CLINICAL CANCER RESEARCH

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)

(2015) Koji Kurose et al.   Journal of Thoracic Oncology

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

(2015) M. D. Sharma et al.   Science Advances

PD-1 regulates extrathymic regulatory T-cell differentiation

(2014) Xiufen Chen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Enhanced suppressor function of TIM-3+FoxP3+regulatory T cells

(2014) Anne-Sophie Gautron et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

(2014) Michinori Ogura et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of self-reactive CD8+T cells with an anergic phenotype in healthy individuals

(2014) Yuka Maeda et al.   SCIENCE

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients

(2013) H-B Jie et al.   BRITISH JOURNAL OF CANCER

High expression of FOXP3 in primary melanoma is associated with tumour progression

(2013) A.L. Gerber et al.   BRITISH JOURNAL OF DERMATOLOGY

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers

(2013) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells

(2011) Hiroyuki Tao et al.   LUNG CANCER

Perturbations of both nonregulatory and regulatory FOXP3+ T cells in patients with malignant melanoma

(2010) H. Fujii et al.   BRITISH JOURNAL OF DERMATOLOGY

Tumor-infiltrating lymphocytes, particularly the balance between CD8+ T cells and CCR4+ regulatory T cells, affect the survival of patients with oral squamous cell carcinoma

(2010) Yoshiko Watanabe et al.   ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS

Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma

(2009) H. K. Jensen et al.   CLINICAL CANCER RESEARCH

Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor

(2009) Makoto Miyara et al.   IMMUNITY

FOXP3 Expression and Overall Survival in Breast Cancer

(2009) Andrea Merlo et al.   JOURNAL OF CLINICAL ONCOLOGY

GITR Triggering Induces Expansion of Both Effector and Regulatory CD4+ T Cells In Vivo

(2009) R. W. van Olffen et al.   JOURNAL OF IMMUNOLOGY

Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery

(2008) Tomoki Ito et al.   IMMUNITY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE